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Triosephosphate isomerase (TPI) deficiency is an autosomal recessive disorder caused by various mutations in the gene
encoding the key glycolytic enzyme TPI. A drastic decrease in TPI activity and an increased level of its substrate,
dihydroxyacetone phosphate, have been measured in unpurified cell extracts of affected individuals. These observations
allowed concluding that the different mutations in the TPI alleles result in catalytically inactive enzymes. However, despite
a high occurrence of TPI null alleles within several human populations, the frequency of this disorder is exceptionally rare. In
order to address this apparent discrepancy, we generated a yeast model allowing us to perform comparative in vivo analyses
of the enzymatic and functional properties of the different enzyme variants. We discovered that the majority of these variants
exhibit no reduced catalytic activity per se. Instead, we observed, the dimerization behavior of TPI is influenced by the
particular mutations investigated, and by the use of a potential alternative translation initiation site in the TPI gene.
Additionally, we demonstrated that the overexpression of the most frequent TPI variant, Glu104Asp, which displays altered
dimerization features, results in diminished endogenous TPI levels in mammalian cells. Thus, our results reveal that enzyme
deregulation attributable to aberrant dimerization of TPI, rather than direct catalytic inactivation of the enzyme, underlies the
pathogenesis of TPI deficiency. Finally, we discovered that yeast cells expressing a TPI variant exhibiting reduced catalytic
activity are more resistant against oxidative stress caused by the thiol-oxidizing reagent diamide. This observed advantage
might serve to explain the high allelic frequency of TPI null alleles detected among human populations.
Citation: Ralser M, Heeren G, Breitenbach M, Lehrach H, Krobitsch S (2006) Triose Phosphate Isomerase Deficiency Is Caused by Altered Dimerization–
Not Catalytic Inactivity–of the Mutant Enzymes. PLoS ONE 1(1): e30. doi:10.1371/journal.pone.0000030
INTRODUCTION
Triosephosphate isomerase deficiency has been initially described
in 1965 [1]. It is a unique glycolytic enzymopathy with autosomal
recessive inheritance that is characterized by chronic haemolytic
anaemia, cardiomyopathy, susceptibility to infections, severe
neurological dysfunction, and, in most cases, death in early
childhood [2]. Thirteen different mutations in the respective gene,
which is located at chromosome 12p13 and encodes the ubiquitous
housekeeping enzyme triosephosphate isomerase (TPI), have been
discovered so far [2,3]. TPI is a crucial glycolytic enzyme and
catalyzes the interconversion of dihydroxyacetone phosphate
(DHAP) and glyceraldehyde-3-phosphate. A marked decrease in
TPI activity and an accumulation of DHAP have been detected in
erythrocyte extracts of homozygous and compound heterozygous
TPI deficiency patients. Remarkably, heterozygous individuals are
clinically unaffected, even if their residual TPI activity is reduced
to about 50% compared to normal activity [2,4,5]. Moreover, the
frequency of heterozygous unaffected individuals in all human
populations investigated is significantly higher than expected from
the rare incidence of homozygous or compound heterozygous TPI
deficiency patients [5–9]. Interestingly, mice studies demonstrated
that mutations resulting in catalytically inactive TPI variants (null
alleles) led to early prenatal lethality in the homozygous state, an
incidence that might also arise in humans [7,10–12].
Bioinformatic analyses have predicted that the human patho-
genic mutations, which are not restricted to a specific domain or
region within the enzyme, could affect the substrate binding site or
the dimerization interface of TPI [2,13]. The most prominent
missense mutation detected in TPI deficiency patients occurs at
codon 104 in the TPI gene encoding aspartic acid instead of
glutamic acid within the enzyme (Glu104Asp variant) and
accounts for approximately 80% of mutant alleles within Northern
European kindreds with clinical TPI deficiency [14,15]. Re-
markably, this variant is the only one observed to be homozygous
among TPI deficiency patients. Other amino acid exchanges in
the TPI protein, such as Cys41Tyr and Ile170Val, have been
predicted to interfere with both the substrate binding and the
dimerization site possibly affecting the catalytic activity plus
molecular stability of TPI; both pathogenic TPI variants have
been identified in unrelated European kindreds [2,13,15].
Furthermore, other missense mutations like a mutation at codon
240 in the TPI gene encoding leucine instead of phenylalanine
within the enzyme (Phe240Leu variant) could have an effect on the
substrate binding site. Other mutations, for instance, the
pathogenic TPI variants Gly122Arg or Val154Met could not be
assigned to defined domains. However, Perry and Mohrenweiser
showed that the Gly122Arg TPI variant, which was identified as
an electromorphic variant by screening 3,400 persons in
a Caucasian population, is a thermolabile enzyme possibly
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mutation has been identified in a French family (Met1_AAG
mutation, TPI Paris) as well as a frame shift mutation at codon 28
or mutations within the upstream region of the TPI gene [3,17].
To date, the best-studied family affected with TPI deficiency is
a Hungarian family in which two germ-line identical compound
heterozygote brothers have inherited a missense mutation at
codon 240 encoding the Phe240Leu TPI variant and a nonsense
mutation at codon 145 (Glu145TER) leading to a truncated TPI
protein [18,19]. Interestingly, these brothers are suffering from an
atypical moderate form of TPI deficiency, although both have an
extremely reduced activity of TPI with less than 5% of normal
enzyme activity and a particularly high level of cellular DHAP.
Strikingly, only one of the brothers has developed neurological
symptoms indicating that the two mutations alone cannot explain
the variance in clinical symptoms [18,19]. In order to gain insight
into the molecular processes causing the different phenotypes of
the two brothers, studies have been performed that demonstrate
variations in the levels of antioxidants [20], in lymphocyte TPI
activity [19], in red blood cell membrane fluidity and enzyme
activities and in the molecular composition of phospholipid
subclasses between the two brothers [21,22]. Moreover, it has
been discovered that the Phe240Leu TPI variant binds with higher
affinity to a yet unidentified component of the red blood cell
membrane and to microtubules in comparison to wild-type TPI,
leading to the assumption that this process could contribute to the
extremely low TPI activity in the disease state [23].
According to the above-mentioned data, it is quite obvious that
further functional analysis of the different TPI variants is
mandatory for comprehending the molecular mechanisms un-
derlying pathogenesis in TPI deficiency.
METHODS
Plasmid construction and mutagenesis
We used the cDNA clones pOTB7-MGC14348 (IR-
ALp962K2120 (RZPD); accession number BC007812) and
plasmid pACT2-NTint5, which was isolated from a human fetal
brain cDNA library (Clontech) for the generation of the different
TPI expression plasmids described in this study. Constructs
encoding the TPI variants TPI Met1_AAG (TPI Paris) or TPI
Phe240Leu, respectively, were produced by PCR using oligonu-
cleotides introducing the respective mutation as indicated in the
Supporting Information. To construct expression plasmids encod-
ing the TPI variants Cys41Tyr, Glu104Asp, Gly122Arg and
Ile170Val, the diverse mutations were introduced via PCR using
the respective oligonucleotide pairs, which overlap in 59 to 39
direction as well as in 39 to 59 direction. Then, the two resultant
PCR fragments were utilized as DNA templates for a subsequent
PCR applying oligonucleotides designed for the amplification of
the full coding sequence of TPI (please refer to the Supporting
Information for oligonucleotide sequences). Afterwards, the DNA
fragments were purified and subcloned into the BamHI and XhoI
sites of the centromeric expression vector p416GPD (GeneBank
accession number DQ269148, [24]) or into the BamHI and XhoI
sites of the high-copy expression vector p426GPD, respectively
(DQ019861, [24]).
For the directed yeast two-hybrid analysis, we generated the
respective bait and prey constructs encoding the various LexA-TPI
or AD-TPI fusion proteins by ligating the different DNA
fragments amplified by PCR into the SalI and NotI sites of the
bait plasmid pBTM117c or the prey plasmid pACT4-1b.
To create the mammalian expression plasmids encoding an N-
terminal fragment of human TPI fused to the green fluorescent
protein (GFP), the first 200 bp of the TPI coding sequences were
amplified via PCR using the oligonucleotide pair TPI-pEGFPN1-
s-Sal1 and TPI-pEGFPN1-as-BamH1, TPIMet1_AAG-pEGFPN1-s-
Sal1 and TPI-pEGFPN1-as-BamH1 for introducing a mutation at
the start codon or TPISer3_TER-pEGFPN1-s-Sal1 and TPI-
pEGFPN1-as-BamH1 for introducing an artificial stop codon.
Subsequently, the PCR fragments were purified and subcloned
into the SalI and BamHI sites of the expression vector pEGFP-N1
(Clontech, U55762).
The mammalian expression plasmids pTL-Flag-TPI-WT and
pTL-Flag-TPI-Glu104Asp were generated by subcloning the
corresponding DNA fragments from pACT-TPI-WT or pACT-
TPI-Glu104Asp into the XhoI/NotI sites of the vector pTL-FlagC,
respectively. PCR was performed under conditions described
earlier [25] and all resultant products were verified by sequencing.
Yeast strains and cultivation
Wild-type strains BY4741 (MATa his3D1 leu2D0 met15D0 ura3D0)
[26] and L40ccua (MATa his3D200 trp1–901 leu2–3,11 gal8 canR
cyh2R) [27] were grown in rich medium (YPD) supplemented with
2% glucose. For the generation of the Dtpi1 strain MR100 (MATa
his3D1 leu2D0 met15D0 ura3D0 LEU2::tpi1) the LEU2 coding
sequence was amplified via PCR using the plasmid pACT2
(Clontech) as DNA template and the oligonucleotides LEU2::tpi-s
and LEU2::tpi-as that each encompasses a 35 nucleotide region
homologous to the TPI1 coding sequence. After transformation of
BY4741 cells via the lithium acetate method [28], transformants
were selected on SC
-leu medium (synthetic complete medium
without leucine) supplemented with 3% (v/v) ethanol/0.1% (v/v)
glucose, because yeast cells deficient for the Tpi1 enzyme are
unable to grow on medium solely supplemented with glucose as
carbon source [29–31]. To verify the gene replacement of the
TPI1 coding sequence, yeast clones exhibiting no growth on media
supplemented with glucose as carbon source have been selected
and the correct insertion of the DNA fragment was confirmed by
PCR and by western blot analysis using a polyclonal TPI serum
(1:4000, [32]). The preparation of yeast genomic DNA, ethanol
lysates, SDS-PAGE and immunoblotting were performed using
standard protocols as described earlier [33,34]. To further exclude
a second integration of the LEU2 marker gene in the genome of
the generated Dtpi1 strain, the wild-type yeast TPI1 gene was
recombined back into the TPI1 locus and transformants were
tested for the loss of leucine prototrophy. One Dtpi1 yeast clone
that has been verified by this set of experiments was named
MR100 and used for our experimental approaches. If not
indicated otherwise, all Dtpi1 cells were grown in media
supplemented with 3% ethanol and 0.1% glucose.
For the complementation analyses, we transformed the Dtpi1
strain MR100 with centromeric plasmids for the expression of the
human TPI variants (Met1_AAG, Cys41Tyr, Glu104Asp,
Gly122Arg, Ile170Val and Phe240Leu) as indicated and selected
single colonies on SC
-leu-ura synthetic media supplemented with
3% ethanol/0.1% glucose. Then, the obtained transformants were
transferred onto media plates containing glucose as carbon source
allowing only yeast cells with functional TPI to grow as well as
onto plates containing 3% ethanol/0.1% glucose as control. For
this analysis, centromeric plasmids were used for cloning purposes,
since these plasmids are known to be highly stable in yeast and are
generally present as a single copy per yeast cell [24]. To prevent
unwanted regulatory effects in our analyses, the constitutive GPD
promoter was chosen for the expression of exogenous TPI.
Additionally, to evaluate the biological reliability of our system, we
expressed yeast Tpi1 from a centromeric plasmid in the strain
MR100 as well. Enzymatic Tpi activity was determined as
Analysis of TPI Variants
PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e30described below and compared to the enzyme activity of wild-type
yeast strain BY4741. No significant differences in Tpi activity were
observed in case the Tpi1 enzyme was expressed from the
centromeric plasmid or from the genome (data not shown).
Resistance of Dtpi1 yeast expressing wild-type or the different
pathogenic TPI variants to oxidants was analyzed as described
earlier [35]. Briefly, the respective yeast cultures were grown to
stationary phase and serially diluted to OD600 values of 3.0, 1.0,
0.3 and 0.1. Then, 10 ml aliquots of each culture were spotted onto
SC plates containing various concentrations of hydrogen peroxide
(1–4 mM; in 0.5 mM steps) tert-butyl hydroperoxide (0.6–2 mM;
0.2 mM steps), cumene hydroperoxide (0.05–0.25 mM; 0.05 mM
steps) and diamide (1.2–1.9 mM; 0.1 mM steps). Sensitivity was
determined by comparing the growth between the different strains
after plates were incubated for 3 days at 28uC. Aberrant
enrichment of reactive oxygen species was determined by
dihydroethidium staining of yeast as described earlier [35].
Directed yeast two-hybrid analysis
To investigate the dimerization behavior of the different
pathogenic TPI variants, we exploited the yeast two-hybrid
system. We generated a number of bait and prey plasmids as
described above and in the Supporting Information. These
plasmids were used to transform the yeast strain L40ccua to
express the different bait and prey proteins in various combina-
tions as indicated in the corresponding figures. Transformants
were selected on SC media lacking tryptophan and leucine. To
analyze the activity of the reporter genes, yeast clones were spotted
onto SC medium lacking tryptophan, leucine, histidine and uracil.
Growth of yeast on selective media was analyzed after incubation
of plates for 48–72 h at 30uC. The lacZ reporter gene activity was
analyzed using an assay based on o-nitrophenyl-b-D-galactopyr-
anoside (Applichem) as described earlier [36]. For the detection of
the bait and prey proteins in the immunoblot analysis, the Gal4AD
antibody (Sigma, 1:5000) or the polyclonal lexA serum ([36],
1:5000) was used.
TPI activity assay
To measure the catalytic activity of the human TPI variants in
yeast, an enzyme-coupled assay based on a protocol developed by
Maitra and Lobo was performed [37]. Briefly, the same numbers
of yeast cells from logarithmically grown cultures were collected.
Then, the cells were washed and frozen at 280uC. After thawing,
the cells were resuspended in PBS, pH 7.4 containing a protease
inhibitor cocktail (‘‘Complete’’, Roche) and lysed using glass beads
(425–600 mm, Sigma). The total protein concentration for each
yeast lysate was determined using a Bradford assay (Biorad). Then,
equal protein concentrations were added to PBS buffer containing
1 U glycerol-3-phosphate dehydrogenase and 0.3 mM NADH
(Sigma). Subsequently, the enzymatic reaction was started by
addition of 10 ml 40 mM glyceraldehyde-3-phosphate (Sigma).
The oxidation of NADH was followed measuring the OD340 in 5 s
intervals for 3 min using a spectrophotometer (Amersham
Ultrospec). Afterwards, the enzymatic activity of TPI under
steady-state conditions was calculated as average substrate
conversion per minute and the activity of the pathogenic TPI
variants was compared to the activity of the wild-type enzyme.
Mammalian cell culture and transfection
COS1 cells were grown in Dulbecco’s modified Eagle medium
(DMEM, Gibco) supplemented with 5% fetal bovine serum,
50 U/ml penicillin and 50 mg/ml streptomycin (Biochrom) in
a humidified 5% CO2 atmosphere at 37uC. Transfection was
performed using Polyfect (Qiagen) as recommended by the
manufacturer. To prepare cell lysates, the cells were washed in
PBS and lysed in a buffer composed of 50 mM Tris-HCl, 100 mM
NaCl, 5 mM MgCl2, 0.5% NP40, 1 mM EDTA, pH 8.8, 25 U/
ml benzonase (Merck) and 2.5% protease inhibitors (‘‘complete’’,
Roche). SDS-PAGE and immunoblotting were performed as
described [34]. GFP fusion proteins were detected using a mono-
clonal GFP antibody (Roche, 1:2000) and FLAG-tagged fusion
proteins were visualized by using a polyclonal antibody directed
against the FLAG tag (Sigma, 1:5000). Tubulin was detected using
a monoclonal antibody (Sigma, 1:2000) and endogenous TPI was
detected by using a polyclonal serum ([32], 1:5000).
Structural visualization
TPI structural coordinates were obtained from Kinoshita et al
(MMDB: 32814, [38] ) and visualized using the Cn3D software
package (NCBI), version 4.1.
RESULTS
Human wild-type and pathogenic TPI variants
complement the loss of yeast Tpi1 in vivo
Structure function relationship investigations have predicted that
the mutations identified to be responsible for TPI deficiency may
affect the tertiary or quaternary structure of TPI, hence, resulting
in a strong reduction in the catalytic activity of the enzyme as
determined within affected individuals; however, they are not
restricted to a specific domain or region within the enzyme
([2,13,14] and Fig. 1). Nevertheless, patient’s metabolites do highly
depend on the genetic background and environmental factors.
Therefore, a model system allowing study of the enzymatic and
functional properties of wild-type and pathogenic TPI variants
without additional side effects due to differing environment and
genetic background is required to gaining insights into the
molecular mechanism implicated in TPI deficiency.
Since it is not feasible to measure the enzymatic activity of one
particular TPI enzyme in mammalian cell lines without further
endogenous TPI, we decided to exploit yeast as a model system
allowing this, since such an approach will give initial insights into
potential variations in the enzymatic functionality of the different
TPI variants. As described in the Methods section, we have
generated the Dtpi1 strain MR100 deleted for the yeast TPI1 gene
in the haploid BY4741 strain background by a single gene
replacement approach. To address the question whether the
human wild-type and the pathogenic TPI variants may comple-
ment the loss of yeast Tpi1 protein, we transformed this strain with
centromeric plasmids for the expression of human wild-type or six
representative pathogenic TPI variants as indicated. We observed
that yeast cells expressing human wild-type TPI were viable on
glucose media, while yeast cells containing the empty vector did
not grow on glucose media indicating that the human wild-type
enzyme complements the loss of the yeast TPI1 gene (Fig. 2A).
Remarkably, with the exception of the Met1_AAG TPI variant, all
pathogenic TPI variants were viable on glucose plates demon-
strating functional activity of these enzymes.
Given that a missense mutation in the yeast TPI1 gene, which
eliminates the catalytic activity of the Tpi1 protein, leads to the
inhibition of the inositol synthesis pathways resulting in sensitivity
to the drug lithium [39], we dropped 5-fold serial dilutions of the
Dtpi1 strain MR100 expressing the various TPI variants on glucose
media supplemented with different concentrations of lithium
chloride (Fig. 2B). As expected, we did not observe significant
growth differences between the various yeast strains even at high
Analysis of TPI Variants
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functionality of the pathogenic TPI variants.
Finally, we investigated the catalytic activity of the wild-type
and the pathogenic TPI variants in MR100 yeast cells. The
Dtpi1 cells expressing the pathogenic TPI variants Cys41Tyr,
Glu104Asp, Gly122Arg or Phe240Leu, respectively, exhibited
catalytic activity in vivo that was comparable to the catalytic activity
of the wild-type protein (Fig. 3). However, yeast cells expressing
the Ile170Val TPI variant showed a strong reduction in catalytic
activity compared to the wild-type protein and the other
pathogenic TPI variants. To rule out that a low intracellular
protein level of the Ile170Val TPI variant causes this diminished
activity in yeast, we analyzed the expression levels of the different
TPI variants in yeast by immunoblot analyses. No differences were
detected demonstrating that the decrease in the enzymatic activity
of the Ile170Val TPI variant is based on reduced enzymatic
activity per se (data not shown). Nevertheless, this residual activity
of about 30% is sufficient to suppress the growth defect of Dtpi1
yeast cells on glucose medium as presented in Fig. 2.
Indications for an alternative translation initiation
start site in the TPI mRNA
The quite evident discrepancy between patient measurements and
in vitro data [40] and our findings in yeast clearly support the
assumption that other cellular processes are required to cause the
extremely low TPI activity measured in patients. On the one hand,
a protein’s function and activity depends upon the association with
its diverse interaction partners occurring in the different cellular
compartments. Furthermore, functional diversity of proteins can
also be regulated at the translational level due to alternative
translation initiation sites within one mRNA transcript probably
resulting in protein variants with novel functional properties [41].
Alternative translational start sites occur at a higher frequency
within the first 20 codons compared to the frequency in down-
stream regions [42,43]. Interestingly, we have noticed that the
NetSTART prediction server (http://www.cbs.dtu.dk/services/
NetStart), which is based on an algorithm for the prediction of
translational start sites [44], gives an exceptionally high confidence
score of 0.700 for the ATG codon encoding MET14 within the
TPI protein compared to the value of 0.741 for the first start
codon (Fig. 4A). Therefore, we analyzed whether the second ATG
codon might function as an alternative translational initiation site
within the TPI mRNA. To test this, we generated yeast plasmids
in which (i) the first ATG codon of the TPI gene was replaced by
an AAG (as observed in the TPI Paris family), (ii) an artificial stop
codon was placed at codon position 3, and plasmids encoding the
(iii) wild-type TPI or (iv) TPI2ndATG as presented in Fig. 4A. After
transformation of these plasmids into the Dtpi1 yeast strain,
transformants were plated on SC
-ura medium supplemented with
3% ethanol/0.1% glucose. Afterwards, ethanol lysates of the
different yeast cultures were prepared and the expression level of
the different TPI proteins was analyzed by immunoblotting. Wild-
type TPI and TPI2ndATG are highly expressed in yeast as shown in
Fig. 4B. Interestingly, the TPI variant TPIMet1_AAG was also
expressed in yeast demonstrating that the second ATG codon in
the TPI gene can be used as translational start site. However, no
expression of the TPISer3_TER variant was observed in yeast,
hence, this observation could be based on the high activity of
nonsense-mediated mRNA decay in yeast [45]. To confirm the
use of the second ATG codon in the TPI gene as alternative
translational start site in mammalian cell lines, we generated fusion
Figure 1. Structural model of human TPI. (Upper panel) The pathogenic TPI variants Cys41Tyr, Glu104Asp, Gly122Arg, Ile170Val and Phe240Leu
were assigned to the crystal structure of human TPI generated by Kinoshita et al [38]; NT: amino terminus. (Lower panel) Appearance of pathogenic
TPI variants among TPI deficiency patients (c.h.: compound heterozygous; n.d.: not determined).
doi:10.1371/journal.pone.0000030.g001
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containing the mutations described above fused to GFP.
Afterwards, COS1 cells were transfected with the respective
expression plasmids or with the empty plasmid pEGFP-N1 and
incubated for two days to allow expression of the recombinant
proteins. Cell lysates were prepared and subsequently analyzed by
immunoblotting (Fig. 4C). Both fusion proteins TPIMet1_AAG-GFP
and TPISer3_TER-GFP were expressed at similar levels compared
to the TPIWT-GFP protein demonstrating that the second ATG
codon within the TPI gene can also be used as a translational
initiation site in mammalian cells.
To this end, we addressed the question whether the TPI2ndATG
variant shows evidence of glycolytic functionality. Again, we set up
to exploit our yeast model and transformed Dtpi1 yeast cells with
the plasmid p416GPD-TPI2ndATG to express this variant in yeast.
However, yeast cells expressing TPI2ndATG were unable to grow
on glucose medium indicating that this protein variant has no
catalytic activity (Fig. 4D).
Dimerization behavior of TPI is affected by the
different mutations
Abnormal dimerization behavior of the pathogenic TPI variants
has often been discussed as a feature in the pathogenesis of TPI
deficiency due to the fact that several mutations within the TPI
gene could influence the dimerization properties of the enzyme
[2], e.g., bioinformatic predictions based on domain assignments
suggested that the most common mutation at position 104 in the
TPI gene, which is located in close proximity to the TPI
dimerization interface, might affect the dimerization property of
TPI ([2,14] and Fig. 1). However, experimental support for this
assumption is lacking. To address this aspect, we exploited the
yeast two-hybrid system, since this system allows not only the
investigation of the direct interaction between proteins, but also
the relative quantification of altered protein interactions
[36,46,47]. First, we generated constructs encoding the bait fusion
protein LexA-TPI or the prey fusion protein AD-TPI to analyze
whether dimerization of TPI can be monitored in a directed yeast
two-hybrid study and transformed the yeast strain L40ccua with
the respective plasmids. Transformants were isolated and the
activity of the reporter genes was monitored via growth on SC
medium lacking histidine and uracil. We observed that yeast cells
co-expressing LexA-TPI and AD-TPI grew on SC
-trp-leu-his-ura
medium demonstrating activity of the respective reporter genes
(Fig. 5A, left panel). In addition, expression of the lacZ reporter
gene was indicated by a blue color shift in a membrane-based b-
galactosidase assay. No activation of the reporter genes was
observed in yeast cells expressing the fusion protein LexA-TPI and
the AD domain alone demonstrating that complex formation of
TPI occurs in the yeast two-hybrid system. Moreover, we analyzed
whether wild-type TPI and the TPI2ndATG variant do interact in
this system. Yeast cells co-expressing the fusion proteins LexA-TPI
Figure 2. Human wild-type and pathogenic TPI variants can substitute for yeast TPI1. A) MR100 yeast cells (Dtpi1) were transformed with the
various p416GPD-based expression plasmids encoding wild-type human TPI as well as the pathogenic variants Met1_AAG, Cys41Tyr, Glu104Asp,
Gly122Arg, Ile170Val or Phe240Leu, respectively, and plated on minimal SC
-leu-ura medium supplemented with 3% ethanol/0.1% glucose. Afterwards,
single yeast clones were selected and grown as represented by the schemes on SC
-leu-ura medium plates supplemented either with 2% glucose or
with 3% ethanol/0.1% glucose at 30uC. B) MR100 Dtpi1 yeast cells expressing wild-type TPI or the different pathogenic TPI variants were grown until
logarithmic phase. Then, the same cell number of each culture was spotted as 5-fold serial dilutions onto glucose media or onto glucose media
supplemented with different concentrations of lithium chloride. Plates were incubated for 3 days at 30uC and growth of the different yeast strains
was analyzed.
doi:10.1371/journal.pone.0000030.g002
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demonstrating that the glycolytic inactive TPI2ndATG variant
associates with wild-type TPI. However, the observed b-galacto-
sidase activity resulting from the interaction between wild-type
TPI and the TPI2ndATG variant was lower compared to the b-
galactosidase activity measured in yeast co-expressing wild-type
TPI proteins (Fig. 5A, middle panel). To confirm that the
differences in lacZ reporter gene activity were not due to different
expression levels of the various bait or prey proteins, we analyzed
the intracellular levels by immunoblotting and observed no
significant differences in intracellular protein concentrations
(Fig. 5A, right panel).
In the next step, we investigated whether the mutations within the
TPI gene might affect the dimerization behavior of the protein by
measuring the relative activity of the lacZ reporter gene, which
indicates the relative strength of a protein-protein interaction [47].
The yeast strain L40ccua was transformed with the bait construct
encoding LexA-TPI in combination with prey constructs encoding
the TPI variants AD-Cys41Tyr, AD-Glu104Asp, AD-Gly122Arg,
AD-Ile170Val or AD-Phe240Leu, respectively. The relative activity
of the lacZ reporter gene measured in yeast co-expressing LexA-TPI
in combination with AD-Gly122Arg or AD-Phe240Leu, respective-
ly, was not significantly altered in comparison to yeast co-expressing
LexA-TPI and AD-TPI suggesting that these mutations were not
affecting the dimerization behavior with wild-type TPI (Fig. 5B,
upper panel). Interestingly, a slightly enhanced b-galactosidase
activity was observed in yeast co-expressing LexA-TPI and AD-
Ile170Val, whereas a strong enhancement was measured in yeast
expressing the fusion proteins LexA-TPI and AD-Cys41Tyr. In
addition, the interaction between LexA-TPI and AD-Glu104Asp
was greatly reduced as monitored by the strong reduction in the
activity of the lacZ reporter gene. Again, analysis of the intracellular
levels of the bait and prey proteins by immunoblotting demonstrated
that all fusion proteins were expressed in yeast at similar levels
(Fig. 5B, lower panel). Thus, these results clearly demonstrated that
some mutations in the TPI gene do indeed lead to an altered
dimerization behavior of the TPI enzyme.
Since the Glu104Asp TPI variant is the most common
pathogenic TPI variant accounting for approximately 80% of
TPI deficiency cases and is the only variant identified to occur in
a homozygous state [2], we further explored the interaction
properties between this variant and the other pathogenic TPI
proteins. We generated a bait plasmid encoding LexA-Glu104Asp
and expressed this fusion protein in combination with the various
AD fusion proteins as indicated (Fig. 5C). As expected from the
results presented in Fig. 5B, the b-galactosidase activity measured
in the respective yeast clones was considerably lower compared to
the corresponding yeast clones expressing wild-type TPI as bait.
Furthermore, no significant alterations in the dimerization
properties between the fusion protein LexA-Glu104Asp and the
AD-TPI variants Cys41Tyr, Glu104Asp, Gly122Arg, or Phe240-
Leu, respectively, were detected. Interestingly, yeast co-expressing
LexA-Glu104Asp and AD-Ile170Val exhibited a significantly
higher b-galactosidase activity. To this end, we also analyzed the
dimerization behavior of wild-type TPI and the TPI2ndATG variant
carrying the different mutations (Fig. 5D). Yeast co-expressing
wild-type TPI and the different TPI2ndATG variants all displayed
a reduced dimerization behavior in comparison to yeast cells
expressing wild-type TPI and TPI2ndATG proteins. Even here,
dimerization was most affected by the Glu104Asp TPI variant. In
sum, our results indicate that the different pathogenic mutations
highly influence the dimerization behavior of human TPI under
recombinant in vivo conditions.
Overexpression of the Glu104Asp TPI variant results
in reduced expression levels of endogenous TPI
The most frequent TPI variant, Glu104Asp, displays strong
defects in the dimerization properties compared to wild-type TPI.
This suggests that regulatory processes due to aberrant protein
dimerization could contribute to the pathogenesis of TPI
deficiency, and therefore we directly investigated whether over-
expression of this variant would have an impact on the regulation
of endogenous TPI. Therefore, we transfected COS1 cells with
plasmids designed for the expression of FLAG-tagged wild-type or
pathogenic TPI enzyme. Then, cell lysates were prepared and
analyzed by immunoblotting (Fig. 6). Strikingly, in comparison to
overexpressed wild-type TPI, a strong reduction in the endoge-
nous TPI level was detected in case the Glu104Asp variant was
overexpressed (upper panel). Thus, this result clearly demonstrates
that endogenous wild-type TPI is deregulated in the presence of
a pathogenic TPI variant exhibiting altered dimerization proper-
ties, and hence, one could conclude that this apparent feedback
mechanism is potentially accountable for the reduced TPI activity
measured in the cell extracts of TPI deficiency patients.
Reduced TPI activity results in increased cellular
resistance against the thiol-oxidizing drug diamide
Accumulation of reactive oxygen species (ROS) influences
chronological and replicative aging in yeast and plays an
important role in the pathogenesis of age related disorders in
humans [48–50]. Interestingly, increased chronic oxidative stress
has been detected in a severely affected TPI deficiency patient as
well [20]. In the light of this observation we investigated whether
the different pathogenic mutations in the TPI gene might cause
intracellular accumulation of ROS in exponentially growing Dtpi1
Figure 3. Pathogenic TPI variants display catalytic activity in vivo.
MR100 Dtpi1 yeast cells expressing wild-type as well as the pathogenic
TPI variants Cys41Tyr, Glu104Asp, Gly122Arg, Ile170Val or Phe240Leu
were grown until the logarithmic phase and equal cell numbers were
collected. Afterwards, the enzymatic assay was performed as described
in the Methods section. The catalytic activity of each pathogenic TPI
variant was compared to the activity of the wild-type enzyme. Each
column represents the mean value of multiple measurements of 4
different yeast clones. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0000030.g003
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no significant differences in red flurorescence between the yeast
strains expressing wild-type or the pathogenic TPI variants were
observed (data not shown). Finally, we analyzed the resistance of
the different yeast strains to oxidants such as hydrogen peroxide,
tert-butyl hydroperoxide, cumene hydroperoxide and diamide. No
differences in the growth rates between the different yeast strains
was monitored on medium containing different concentrations of
hydrogen peroxide, tert-butyl hydroperoxide or cumene hydro-
peroxide, respectively (data not shown). However, we discovered
that treatment of the different yeast strains with the thiol-oxidizing
drug diamide had an effect. Strikingly, yeast cells expressing
Ile170Val TPI, the variant exhibiting a reduced catalytic activity
as shown in Fig. 3, were resistant to diamide treatment in
comparison to strains expressing wild-type or the other pathogenic
TPI variants (Fig. 7). Only yeast cells expressing this TPI variant
were able to grow on medium containing 1.7 mM diamide. Thus,
this result indicates that a decrease in the catalytic activity of the
TPI enzyme mediate cellular resistance against oxidative stress
caused by diamide treatment.
DISCUSSION
Metabolic studies demonstrated that the activity of the TPI
enzyme is reduced to 3–20% of the wild-type value as measured in
unpurified erythrocyte or muscle extracts of TPI deficiency
patients [2,13,51]. However, some discrepancies between mea-
surements performed with patients’ erythrocytes and a number of
observations made in experimental systems and theoretical
analyses have been reported over the last few years. As
aforementioned, the frequency of TPI null alleles is much higher
as the rare incidence of TPI deficiency [5–9], and in vitro
measurements of a mutant TPI variant purified from E. coli
demonstrated that the purified TPI protein carrying the
Phe240Leu mutation exhibited a 6-fold higher activity than
expected from the measurements performed with the patient
erythrocyte extract [40]. Moreover, theoretical calculations
demonstrated that the extremely high DHAP level observed in
patients’ erythrocytes does not correlate with the measured
residual TPI activity [13]. Since patients’ metabolites highly
depend on the genetic background and environmental factors, we
have generated an in vivo system allowing analysis of the enzymatic
activity of wild-type or pathogenic TPI variants inside a cell
without additional side effects. Utilizing yeast genetics, we
generated a yeast strain deleted for the TPI1 gene enabling us to
investigate the enzymatic and functional properties of a number of
human TPI variants in vivo. We showed that human wild-type as
well as the pathogenic TPI variants Cys41Tyr, Glu104Asp,
Gly122Arg, Ile170Val and Phe240Leu, respectively, all suppress
the growth defect of Dtpi1 yeast on glucose medium providing the
first in vivo evidence that these pathogenic variants exhibit catalytic
activity. We corroborated this result by demonstrating that the
respective yeast clones are not hypersensitive to lithium chloride,
a phenotype caused by inactivation of the Tpi1 enzyme due to
inhibition of the inositol biosynthesis pathway [39]. Finally, we
Figure 4. An alternative translation initiation start site within the TPI mRNA. A) The first 17 codons of the human TPI sequence and the netstart
scores are presented. The introduced mutations are indicated in bold letters. B) MR100 Dtpi1 yeast cells were transformed with the respective
plasmids encoding TPI, TPIMet1_AAG, TPISer3_TER or the variant TPI2ndATG. Ethanol lysates were prepared from logarithmically growing yeast cultures and
the expression level of the different TPI variants was analyzed by immunoblotting using polyclonal a-TPI serum. Please note that no sample was
loaded in case of the lane marked with a dash. C) COS1 cells were transfected with the plasmids pEGFP-N1, pEGFP-N1-TPI, pEGFP-N1-TPIMet1_AAG or
pEGFP-N1-TPISer3_TER. Cell lysates were prepared and the expression level of the different fusion proteins was analyzed by immunoblot using an a-GFP
antibody. D) MR100 Dtpi1 yeast was transformed with expression plasmids encoding wild-type TPI, TPIMet1_AAG or TPI2ndATG. Afterwards, single yeast
clones were selected and grown on the respective SC
-leu-ura plates for 3 days at 30uC as indicated.
doi:10.1371/journal.pone.0000030.g004
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pathogenic TPI variant investigated is not affected as a result of
the mutation in the TPI gene. Interestingly, the pathogenic TPI
variant Ile170Val displayed only about 30% of the wild-type
catalytic activity; hence, this activity is sufficient to suppress the
growth defect of Dtpi1 yeast on glucose medium.
Since our results seem to be in sharp contrast to the measured
TPI activity in unpurified erythrocyte extracts of TPI deficiency
patients at disease stage, they clearly make obvious that regulatory
events rather than enzyme inactivity are the basis for this
enormous reduction in TPI activity. Indeed it has been reported
that binding of TPI to an yet unidentified component of red cell
Figure 5. Dimerization behavior of wild-type and pathogenic TPI variants. A) The yeast two-hybrid strain L40ccua was co-transformed with
plasmids encoding LexA-TPI, AD, AD-TPI or AD-TPI2ndATG as indicated. Afterwards, transformants were spotted on SC media lacking tryptophan and
leucine, onto SC medium lacking tryptophan, leucine, histidine and uracil, or onto nylon membrane for analyzing the activity of the three reporter
genes (left panel). For quantitative analysis of the lacZ reporter gene activity a liquid b-galactosidase assay was performed (middle panel). Each
column represents the mean value of four measurements. Error bars indicate the standard deviation. The expression level of the respective bait and
prey proteins was analyzed by immunoblot analysis using antibodies against lexA or gal4AD (right panel). B) Strain L40ccua was transformed with
plasmids encoding LexA-TPI and AD-TPI or LexA-TPI and the pathogenic variants AD-Cys41Tyr, AD-Glu104Asp, AD-Gly122Arg, AD-Ile170Val or AD-
Phe240Leu, respectively. In C) plasmids encoding the LexA-Glu104Asp protein and AD-WT or LexA-Glu104Asp and the variants AD-Cys41Tyr, AD-
Glu104Asp, AD-Gly122Arg, AD-Ile170Val or AD-Phe240Leu, respectively, were used. LacZ reporter gene activity in B) and C) was measured using
a liquid b-galactosidase assay. D) Dimerization behavior between wild-type TPI and TPI2ndATG variants comprising the corresponding amino acid
exchanges was analyzed as described before. All experiments were repeated twice using yeast cells obtained from independent transformations. The
intracellular level of the various bait or the prey proteins (in B–D) was monitored by immunoblot analysis using antibodies against lexA or gal4AD.
doi:10.1371/journal.pone.0000030.g005
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Jung and co-workers identified human cofilin as interaction
partner of TPI and demonstrated that the Rho activator
lysophosphatidic acid leads to translocation of cofilin along with
TPI to the plasma membrane. This cofilin-TPI complex then
interacts with Na/K-ATPase [52]. Consequently, to elucidate the
pathogenesis of TPI deficiency, it is of enormous importance to
identify cellular factors that interact with TPI, to investigate
whether their association has an effect on the catalytic activity of
TPI, and obviously whether the binding is affected by the various
mutations.
At least three different isoelectric TPI variants encoded by the
single TPI gene have been observed in human red blood cells
[53,54] or mouse-brain capillary endothelial cells [32]. Further-
more, the Alternative Splicing Database (ASD, [55]) predicts three
alternative splice variants for human TPI, but none of them has
been identified experimentally to date. Along these lines, protein
diversity is often generated by utilizing alternative translation
initiation sites [41,43], mainly if a second start site is located within
the first 20 codons [41,42]. The usage of alternative translation
initiation sites have been discussed for disease-causing proteins
such as parkin [56], the prion protein [57] and the breast cancer
antigen BRCA1 [58]. Here, we provided evidence that the second
in-frame ATG codon in the TPI gene encoding MET14 can be
used as an alternative translation initiation site in yeast as well as
in mammalian cells. However, the resulting protein did not
suppress the growth defect of Dtpi1 yeast on glucose medium
indicating that this variant lacks catalytic activity. This result is
not unexpected, since this TPI variant lacks the catalytic lysine
and at least three residues of the intersubunit interface.
Interestingly, a TPI deficiency patient which has inherited
a start codon mutation in combination with the mutation at posi-
tion 104, has a stronger pathology in comparison to Glu104Asp
homozygotes [17].
Structural alterations of the pathogenic TPI variants have often
been speculated to contribute to TPI deficiency as a number of
mutations seem to affect the dimerization interface of TPI which
forms a stable dimer in most investigated organisms [2,13,54]. To
address this issue, we have analyzed the dimerization properties
between wild-type and the pathogenic TPI variants by a quanti-
tative assay that is based on the lacZ gene as reporter. This allows
determination of the relative strength of protein-protein interac-
tions in yeast, however, these values can not be directly correlated
with binding constants (e.g. KD) determined by in vitro measure-
ments [46,47]. We discovered that the dimerization behavior
between wild-type TPI and the two pathogenic variants Cys41Tyr
and Glu104Asp is strongly altered compared to the dimerization
behavior between wild-type proteins. We further observed that the
glycolytically inactive TPI2ndATG variant dimerizes with wild-type
Figure 6. Overexpression of the Glu104Asp TPI variant results in
a reduced expression level of endogenous TPI. COS1 cells were
transfected with pTL-Flag-TPI-WT or pTL-Flag-TPI-Glu104Asp as in-
dicated. After 48h, lysates were prepared and analyzed by immuno-
blotting as described in the Methods section. Loading of equal protein
concentrations was demonstrated by tubulin staining (lower panel). In
addition, similar levels of FLAG-tagged wild-type TPI and FLAG-tagged
Glu104Asp TPI was detected in the respective cell lysates (middle
panel).
doi:10.1371/journal.pone.0000030.g006
Figure 7. MR100 Dtpi1 yeast cells expressing the Ile170Val TPI variant are hyperresistant to diamide. MR100 Dtpi1 yeast cells expressing wild-type
as well as the pathogenic TPI variants Cys41Tyr, Glu104Asp, Gly122Arg, Ile170Val or Phe240Leu were grown to stationary phase, serially diluted to
OD600 values of 3.0, 1.0, 0.3, 0.1 and spotted onto SC medium plates containing different concentrations of diamide. Sensitivity/resistance was
determined by comparing the growth between the different yeast strains after incubating the plates for 3 days at 28uC.
doi:10.1371/journal.pone.0000030.g007
Analysis of TPI Variants
PLoS ONE | www.plosone.org 9 December 2006 | Issue 1 | e30TPI, although at reduced levels in comparison to the dimerization
of wild-type TPI proteins. Finally, we demonstrated that the
dimerization between the pathogenic variants also occurred with
lower stringency as indicated by the relative activity of the lacZ
reporter gene. In the light of these results, it is quite remarkable
that the Glu104Asp TPI variant, which displayed the most
modified dimerization behavior, is the most common variant
observed amongst the affected individuals. Moreover, this variant
is the only TPI variant found homozygous among affected
individuals; all other mutations occur only in the compound
heterozygous state together with the Glu104Asp variant or with an
obvious TPI null allele ([2] and Fig. 1). For example, in the TPI
Paris family, the start codon mutant (ATG to AAG) has been
detected in the heterozygous state with the Glu104Asp variant
[17], the Phe240Leu variant observed in the Hungarian family is
found together with the Glu145TER null allele [18]. Generally,
dimerization between proteins is a substantial process to generate
and regulate cellular functions of proteins [59]. Remarkably, we
discovered that overexpression of the Glu104Asp variant results in
reduced levels of endogenous TPI in mammalian cells. This
finding is exciting since recent studies demonstrated that both
compound heterozygous brothers of the Hungarian family have
reduced TPI mRNA levels compared to their parents and healthy
controls [60] suggesting that altered dimer formation resulting in
a modified feedback regulation of the TPI enzyme could underlie
the pathogenesis of TPI deficiency.
Remarkably, TPI is highly up-regulated under stress conditions
in mammalian cells ([32] and Ralser, unpublished observations).
Regarding this issue, it is important that expression of the
Ile170Val TPI variant with reduced catalytic activity results in
higher resistance of yeast to diamide. Diamide is an oxidant which
is known to stoichiometrically oxidize small molecules including
glutathione (GSH) within red blood cells, but is less effective in
oxidizing protein-integrated cysteines [61]. Therefore, diamide
treatment results in a rapid decrease in intracellular GSH, thus,
leading to oxidative stress [62]. Interestingly, the response
mechanisms of eukaryotic cells to oxidative stress are strictly
dependent on the compound and its downstream effects [63]. This
might explain why yeast cells expressing the TPI variant with
reduced catalytic activity were not resistant to all oxidants
examined. It is noteworthy to mention that in contrast to diamide,
all other oxidants used in this study are hydroperoxides.
Treatment with hydroperoxides leads to the inactivation of the
Tdh3 protein, the most abundant of the three glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) enzymes in yeast, by S-
thiolation, carbonlyation or ADP-ribosylation [64–67]. GAPDH
catalyzes the first downstream reaction after TPI in glycolysis and
remarkably, mutants lacking TDH3 were sensitive to a challenge
with a lethal dose of H2O2 [67]. It is likely that inactivation of
GAPDH after peroxide treatment of yeast cells is forestalling the
protective effect of TPI variants exhibiting reduced catalytic
activity. In this context it is noteworthy to mention that blockage
of glycolysis can force an increased influx of metabolites into the
pentose phosphate pathway resulting in an elevated cellular
NADPH concentration [68,69] and vice-versa that different
mutations introduced in enzymes implicated in this pathway are
leading to oxidant-hypersensitive cells [70]. High intracellular
NADPH levels are beneficial during conditions of oxidative stress,
because NADPH provides the base for several antioxidant
enzymes including the thioredoxins or the glutaredoxin system
[71,72]. As aforementioned, the first downstream enzyme of TPI
in glycolysis, GAPDH, is specifically inactivated after peroxide
treatment of yeast cells [64,66] and this subject is, interestingly,
reflected in mammalian cells as well [65,68].
In the light of the above-mentioned findings it is quite intriguing
that the frequency of heterozygous individuals carrying one
inactive TPI allele is quite high. Several studies demonstrated an
allelic frequency from roughly 0.002 (Caucasian and Japanese
population) to 0.02 (African American population) [5–9]. Indeed
this number implies that 1 out of 2000 newborn individuals from
the latter population would suffer from this tremendous disorder,
but less than 100 individuals have been diagnosed with TPI
deficiency worldwide [6]. A mutagenesis screen in mice identified
four heterozygous TPI mutations that lead to a 50% reduction in
catalytic TPI activity in several tissues examined [12]. However,
each homozygous or compound heterozygous offspring of these
mice, which lacked any detectable phenotypical abnormalities in
the heterozygote state, resulted in early embryonic lethality [12].
These results demonstrated that mutations in the TPI gene
resulting in a catalytic inactive TPI enzyme cause homozygote
embryonic lethality in mice. The human population studies
performed are indicating that this situation is reflected in humans
as well [5,6]. Consequently, the occurring mutations in TPI alleles
of TPI deficiency patients cannot encode catalytically inactive TPI
enzymes. As illustrated and demonstrated in Fig. 8, homozygote
TPI null alleles are lethal, since no homozygotes carrying TPI null
alleles can be detected in mouse and humans [5,12]. Furthermore,
TPI variants with altered dimerization properties and exhibiting
almost normal specific catalytic activity like the Glu104Asp
variant, occur in homozygous states causing TPI deficiency [14]
or in combination with TPI null alleles, for instance, the TPI Paris
(Met1_AAG; heterozygous with Glu104Asp) or TPI Alfortwille
(frameshift at codon 29; heterozygous with Glu104Asp) [17]
representing the compound heterozygote state, whereas heterozy-
gote individuals having inherited a heterozygote null allele in
combination with the wild-type allele are healthy and might have
a heterozygous advantage. Regarding this issue, one should keep
in mind that advantage of heterozygous state has been
Figure 8. Consequences of mutations within human TPI. Homozygous
mutations within TPI affecting enzyme dimerization cause TPI de-
ficiency, whereas homozygous mutations resulting in an inactive TPI
allele are lethal. Compound heterozygous individuals having inherited
one inactive and one allele defective in dimerization properties will
develop TPI deficiency, whereas heterozygote individuals having
inherited a heterozygote null allele have an evolutionary advantage.
(+: wild-type TPI; 2: TPI with aberrant dimerization property; 0: allele
encoding no or a catalytically inactive TPI).
doi:10.1371/journal.pone.0000030.g008
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genetic disorders. Strikingly, the allelic frequency of mutations
causing cystic fibrosis is comparable to the frequency of
heterozygous TPI mutations in the examined Afro-American
population [6,73]. The fact that the yeast strain harboring the TPI
variant with reduced catalytic activity is more resistant to specific
oxidative stress is a first indication that mutations within TPI
alleles resulting in catalytically impaired enzymes could confer an
advantage to certain stress stimuli or other environmental
conditions.
SUPPORTING INFORMATION
Primer Sequences and Plasmids
Found at: doi:10.1371/journal.pone.0000030.s001 (0.06 MB
DOC)
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